With a market cap of $9.3 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of messenger RNA (mRNA) therapeutics and vaccines. Known for its COVID-19 vaccine ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

South African global pharmaceutical giant Aspen Pharmacare has found itself caught in Trump tariff-related market volatility, as it witnessed R22 billion being wiped off its JSE market capitalisation ...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Moderna, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We unpack the full scope of the U.S. budget cuts, from canceled clinical trials and stalled drug approvals to mass layoffs ...

Donald Trump and RFK have caused mayhem in the US medical research market. It's clearing a path for Aussie drug trial contractor IDT.

Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000—until recently. Thanks to changes in Medicare Part D ...

GSK's Q1 2025 earnings will reveal progress in specialty medicines amid regulatory headwinds. Learn what to watch when the ...